<DOC>
	<DOCNO>NCT02532335</DOCNO>
	<brief_summary>OCAPUSH ( EudraCT 2014-002313-33 ) double-blind placebo-controlled parallel-arms study effect obeticholic acid farnesoid X receptor expression jejunum gut microbiota morbidly obese patient healthy volunteer . Obeticholic acid ( OCA , 6-ethyl-chenodeoxycholic acid , INT-747 ) semi-synthetic derivative major human bile acid chenodeoxycholic acid administer orally dose 25 mg/day three week 20 morbidly obese patient await Roux-en-Y gastric bypass 20 healthy volunteer . On day first last dose faeces blood sample analysis bile acid gut microbiota . On day last dose push-enteroscopy perform conscious sedation biopsy take jejunum.These procedure repeat 6 month surgery morbid obese patient . Inclusion criterion male female gender , 20-65 year age morbid obesity ( BMI &gt; 35 kg/m2 ) eligible bariatric surgery . Exclusion criterion liver diseases fatty liver disease , significant morbidity , medication know interact OCA , pregnancy , uncertainty safe reliable contraception , problem understand adhere protocol . The primary objective pharmacodynamic trial study effect OCA expression FXR jejunum small intestinal permeability , fecal bile acid gut microbiota . The secondary objective study effect OCA genome-wide FXR DNA bind site ( cistromics ) global gene expression profile ( transcriptomics ) human jejunum .</brief_summary>
	<brief_title>Obeticholic Acid Morbidly Obese Patients Healthy Volunteers</brief_title>
	<detailed_description>Obeticholic acid administer orally dose 25 mg/day three week 20 morbidly obese patient await Roux-en-Y gastric bypass 20 healthy volunteer . On day first last dose faeces blood sample analysis bile acid gut microbiota . On day last dose push-enteroscopy perform conscious sedation biopsy take jejunum . These procedure repeat 6 month surgery morbid obese patient . Inclusion criterion male female gender , 20-65 year age morbid obesity ( BMI &gt; 35 kg/m2 ) eligible bariatric surgery . Exclusion criterion liver diseases fatty liver disease , significant morbidity , medication know interact OCA , pregnancy , uncertainty safe reliable contraception , problem understand adhere protocol . The primary objective pharmacodynamic trial study effect OCA expression FXR jejenum small intestinal permeability , fecal bile acid gut microbiota . The secondary objective study effect OCA genome-wide FXR DNA bind site ( cistromics ) global gene expression profile ( transcriptomics ) human jejunum .</detailed_description>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>Morbid obesity await gastric bypass surgery , â‰¥35 kg/m2 Male subject , pre , postmenopausal female subject Women childbearing potential include safe reliable contraception use , e.g. , oral contraceptive Patients eligible laparoscopic bariatric surgery Patients must give sign dated write consent participate study base write information pertinent aspects trial provide least 24 hour undertake trial related activity . Chronic liver disease NAFLD ( viral hepatitis , autoimmune liver disease , hemochromatosis , homozygous alpha1antitrypsin deficiency Wilson disease ) Previous gastric small bowel surgery Inflammatory bowel disease Uncontrolled diabetes mellitus ( fast blood glucose &gt; 6.7 mmol/L ) , hypothyroidism hyperthyroidism , significant endocrine disease . Pregnancy . A urine pregnancy test perform day start medication . Women childbearing potential include safe reliable contraception use , e.g. , oral contraceptive . Elevations transaminase ( ALAT/ASAT ) alkaline phosphatase bilirubin 2xULN ( upper limit normal ) day start medication . Other serious disease , include depressive disorder treat medication Patients comply protocol . Hypothyroidism , unless subject clinically euthyroid , receive stable dose thyroid hormone replacement therapy serum TSH within normal range .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FXR</keyword>
	<keyword>bile acid</keyword>
	<keyword>FGF19</keyword>
	<keyword>C4</keyword>
	<keyword>gut microbiota</keyword>
	<keyword>Pharmacodynamics FXR activation small bowel</keyword>
</DOC>